The active phase II trial is studying the efficacy of anti-PD-1 mAb pembrolizumab to treat rare tumors that are metastatic or unresectable with primary outcome measures being tumor nonprogression rate and incidence of adverse events (NCT02721732). This evidence concerns the gene PDCD1 and neoplasm.